HCI vs UPC vs HCWB vs HRTG vs PLMR

For growth investors, Palomar Holdings, Inc.

(PLMR) is the stronger pick with 58. 2% revenue growth year-over-year, versus -97. 9% for HCW Biologics Inc. (HCWB). Heritage Insurance Holdings, Inc. (HRTG) offers the better valuation at 4. 4x trailing P/E (6. 1x forward), making it the more compelling value choice. Analysts rate HCI Group, Inc. (HCI) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Heritage Insurance Holdings, Inc.

(HRTG) is the cheapest at 4. 4x versus Palomar Holdings, Inc. at 15. 8x. On forward P/E, Heritage Insurance Holdings, Inc. is actually cheaper at 6. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Palomar Holdings, Inc. wins at 0. 12x versus Heritage Insurance Holdings, Inc. 's 0. 39x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Heritage Insurance Holdings, Inc.

(HRTG) delivered a total return of +201. 4%, compared to -100. 0% for Universe Pharmaceuticals Inc. (UPC). Over 10 years, the gap is even starker: PLMR returned +498. 1% versus UPC's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Palomar Holdings, Inc.

(PLMR) is the lower-risk stock at 0. 24β versus HCW Biologics Inc. 's 1. 54β — meaning HCWB is approximately 538% more volatile than PLMR relative to the S&P 500. On balance sheet safety, Palomar Holdings, Inc. (PLMR) carries a lower debt/equity ratio of 1% versus 2% for HCW Biologics Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Palomar Holdings, Inc.

(PLMR) is pulling ahead at 58. 2% versus -97. 9% for HCW Biologics Inc. (HCWB). On earnings-per-share growth, the picture is similar: Heritage Insurance Holdings, Inc. grew EPS 214. 4% year-over-year, compared to -1280. 5% for HCW Biologics Inc.. Over a 3-year CAGR, PLMR leads at 38. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

HCI Group, Inc.

(HCI) is the more profitable company, earning 33. 2% net margin versus -146. 8% for HCW Biologics Inc. — meaning it keeps 33. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HCI leads at 47. 7% versus -207. 6% for HCWB. At the gross margin level — before operating expenses — PLMR leads at 73. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Palomar Holdings, Inc. (PLMR) is the more undervalued stock at a PEG of 0. 12x versus Heritage Insurance Holdings, Inc. 's 0. 39x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Heritage Insurance Holdings, Inc. (HRTG) trades at 6. 1x forward P/E versus 11. 9x for Palomar Holdings, Inc. — 5. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HRTG: 39. 1% to $39. 00.

In this comparison, HCI (1.

0% yield) pays a dividend. UPC, HCWB, HRTG, PLMR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, HCI Group, Inc.

(HCI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 39), 1. 0% yield, +436. 8% 10Y return). HCW Biologics Inc. (HCWB) carries a higher beta of 1. 54 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HCI: +436. 8%, HCWB: -99. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (HCI (Financial Services) and UPC (Healthcare) and HCWB (Healthcare) and HRTG (Financial Services) and PLMR (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: HCI is a small-cap high-growth stock; UPC is a small-cap quality compounder stock; HCWB is a small-cap quality compounder stock; HRTG is a small-cap deep-value stock; PLMR is a small-cap high-growth stock. HCI pays a dividend while UPC, HCWB, HRTG, PLMR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.